Comparative Pharmacology
Head-to-head clinical analysis: METHYLPREDNISOLONE versus NAFAZAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHYLPREDNISOLONE versus NAFAZAIR.
METHYLPREDNISOLONE vs NAFAZAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; inhibits phospholipase A2, decreases prostaglandin and leukotriene synthesis; suppresses cytokine production and immune cell activity.
Unknown. It is a purified fatty acid derivative that may modulate inflammatory responses.
4-48 mg/day orally in divided doses; 10-40 mg IV/IM bolus, then 10-40 mg IV q4-6h; high-dose IV pulse: 1 g/day for 3 days.
2.5 mg subcutaneously once daily.
None Documented
None Documented
Plasma: 2.5-3.5 hours; biological half-life (tissue): 18-36 hours due to glucocorticoid receptor-mediated effects; clinical context: anti-inflammatory effects persist beyond plasma clearance
Clinical Note
moderateMethylprednisolone + Digoxin
"Methylprednisolone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMethylprednisolone + Digitoxin
"Methylprednisolone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMethylprednisolone + Deslanoside
"Methylprednisolone may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMethylprednisolone + Acetyldigitoxin
Terminal elimination half-life is 6-8 hours; in moderate renal impairment (CrCl 30-50 mL/min) extends to 12-15 hours.
Renal (primarily as inactive metabolites, <10% unchanged); minor biliary/fecal elimination
Primarily renal excretion (70-80% as unchanged drug), with 15-20% fecal elimination via biliary secretion.
Category D/X
Category C
Corticosteroid
Intranasal Antihistamine/Corticosteroid
"Methylprednisolone may decrease the cardiotoxic activities of Acetyldigitoxin."